New injection could ease sleep apnea and aid weight loss
NCT ID NCT07501832
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an injection called GZR18 in 140 obese adults with moderate-to-severe obstructive sleep apnea who already use a breathing machine (PAP). The goal is to see if the drug improves breathing during sleep, reduces weight, and boosts quality of life compared to a placebo. It is a Phase 3 trial, meaning it is in the final stages before possible approval.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GZR18 injection
- What this could lead to
- If it works, this could offer a new treatment that reduces sleep apnea severity and helps with weight loss in obese patients.
- What could go wrong
- This is an early-stage Phase 3 trial with only 140 participants, so results may not apply to everyone. The drug may cause side effects or not improve sleep apnea significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE SLEEP APNEA (OSA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gan & Lee Pharmaceuticals
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a home sleep test beat the hospital for diagnosing apnea?
- A dual sleep disorder: can one pill boost CPAP success?
- What lies beneath sleep apnea? a deep dive into its hidden health ties
- Can a simple questionnaire spot hidden sleep apnea in millions?
- Wall squats tested as a blood pressure hack for sleep apnea patients
- Blood tests may one day replace sleep studies for apnea